Oncology

Review top news and interview highlights from the week ending May 20, 2022.

Findings from a preclinical study, which are in contrast with the current biphasic recovery model, have implications for both HSC transplantation and gene therapy.

The assistant professor of oncology at UNC School of Medicine discussed the first-in-human study being conducted with CT-0508.

Catch up on the latest news and announcements in cell and gene therapies presented at the annual ASGCT meeting.

Multiple insertions were observed in affected participants, including insertions in the MECOM and PRDM16 genes.

One patient with metastatic pancreatic cancer remains alive on maintenance chemotherapy 3 years after treatment.

Investigators are evaluating the safety, tolerability and preliminary efficacy of CT-0508 in patients with solid tumors and HER2 overexpression.

Further data from Mustang Bio’s phase 1/2 trial will be presented at the EHA 2022 Congress.

Review top news and interview highlights from the week ending May 13, 2022.

Caribou will present the initial data at the upcoming European Hematology Association (EHA) meeting in June.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The cell therapy is the first to come out of the company’s proprietary ARC-SparX platform.

Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial (NCT04372706) with solid tumors, presented recently at the 2022 AACR Annual Meeting.

Tim Lu, MD, PhD, CEO and co-founder of gene circuit company Senti Bio, joins CGTL to discuss his company's approach to creating "smarter" therapies, including its CAR-NK platform.

Marker Therapeutics is taking a multi-antigen approach to developing next-generation T-cell therapies.

Review top news and interview highlights from the week ending May 6, 2022.

Radek Špíšek, PhD, co-founder and chief executive officer of SOTIO Global, and Geoffrey Hodge, chief executive officer of SOTIO BioTech US, join CGTL to discuss its 3 technology platforms and how they are leveraging them to attack the solid tumor micro-environment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

There was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.

Rami Elghandour, chairman and CEO of Arcellx, shares updates on the phase 1 trial of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.

Review top news and interview highlights from the week ending April 29, 2022.

The real-world analysis addresses a clear gap in data from previous and ongoing cell therapy clinical trials.

Several CAR T-cell therapies have proved to be efficacious in hematological malignancies; however, developing a safe and effective CAR T-cell approach for solid tumors has remained a challenge.

The CEO and managing director of Chimeric Therapeutics hopes to contribute to the narrative with a handful of offerings in development across 2 platforms: CORE-NK, which uses allogeneic natural killer cells, and T-cell derived autologous therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

SQZ-PBMC-HPV receives FDA Fast Track Designation for patients with advanced or metastatic HPV16+ solid tumors, following promising early results.

The analysis of data from ZUMA-7 demonstrated significant efficacy for axi-cel over second-line standard treatment.

Pivotal phase 3 findings for ofra-vec in patients with ovarian cancer are anticipated in the second half of 2022.

The gene-edited CAR T-cell therapy is currently being investigated in a phase 2 clinical trial.

Tisa-cel was associated with a more favorable safety profile in the analysis.